COMPANY

Agenus Inc.

HQ: Lexington, MA source · agenusbio.com ↗ · New England

Keywords: oncology tumors cancer Cervical Cancer Renal Cell Carcinoma tuberculosis Ovarian Cancer Prostate Cancer Angiosarcoma Metastatic Pancreatic Ductal Adenocarcinoma Colorectal Cancer Pancreatic Cancer Non-Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Sarcoma Colorectal Cancer Without Liver Metastases Endometrial Cancer Fibrolamellar Carcinoma Non-small-cell Lung Cancer Advanced Melanoma Metastatic Colorectal Cancer Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies Follicular Lymphoma Small Lymphocytic Lymphoma Metastatic Cervical Cancer Herpes Simplex Type 2 NSCLC Stage IV Malignant Melanoma Kidney Cancer Leukemia, Myeloid, Chronic Non-Small-Cell Lung Carcinoma Lung Cancer Pulmonary Cancer Genital Herpes B-Cell Lymphoma malaria chlamydia AGEN2034

Location: Lexington, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$85.0MRaised (2 yrs)31Trials (company is sponsor)29NIH grants

Timeline

Jul 13, 2026 Raise Private placement: $85M (initial closing, as published); deal value up to $340M (not counted as received), announced Jul 13, 2026. Source: SEC filing. source ↗
Jun 3, 2025 Partnership Partnership / licensing: $141M (upfront, as published), announced Jun 3, 2025. Source: SEC filing. source ↗
Jun 3, 2025 Partnership Partnership / licensing: $75M (upfront, as published); deal value up to $50M (kept separate from upfront), announced Jun 3, 2025. Source: SEC filing. source ↗
Mar 27, 2023 Trial start Phase 2: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer source ↗
Dec 12, 2022 Trial start Phase 2: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma source ↗
Nov 30, 2022 Trial start Phase 2: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer source ↗
Jul 19, 2022 Trial start Phase 1: Study of AGEN1571 in Participants With Advanced Solid Tumors source ↗
Oct 4, 2021 Trial start Phase 1: A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors source ↗
Oct 1, 2021 Trial start II: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer source ↗
Aug 2, 2021 Trial start Phase 3: Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) source ↗
2021-02 Trial start Phase 2: AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma source ↗
Dec 10, 2019 Trial start Phase 1: A Study in Subjects With Advanced Solid Tumors source ↗
Sep 26, 2019 Trial start Phase 1: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer source ↗
Jun 1, 2019 Trial start 2: RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer source ↗
May 16, 2019 Trial start 1: Phase 1a Study to Evaluate Immunogenicity of ASV® source ↗
Mar 20, 2019 Trial start Phase 1: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer source ↗
Dec 18, 2017 Trial start Phase 1/Phase 2: A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) source ↗
Oct 4, 2017 Trial start Phase 2: Study of AGEN1884 With Pembrolizumab in 1L NSCLC source ↗
Apr 11, 2017 Trial start Phase 1/Phase 2: A Study of AGEN2034 in Advanced Tumors and Cervical Cancer source ↗
2017-01 Trial start Phase 1: Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer source ↗
2016-04 Trial start Phase 1/Phase 2: AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy source ↗
Oct 29, 2012 Trial start Phase 2: Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes source ↗
2010-01 Trial start Phase 2: Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence source ↗
2006-03 Trial start Phase 1: Trial Evaluating Safety, Tolerability and Immune Response of AG-707 source ↗
2006-03 Trial start Phase 1: Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma source ↗

Showing 25 of 32 dated events.

Upcoming milestones

2027-09 (ESTIMATED) · Phase 2 · A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer · NCT05608044
2028-02 (ESTIMATED) · Phase 2 · A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma · NCT05529316

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $85.0M. Last 2 years.

Jul 13, 2026 Private placement: $85M (initial closing, as published); deal value up to $340M (not counted as received), announced Jul 13, 2026. Source: SEC filing. source ↗
Jun 3, 2025 Partnership / licensing: $141M (upfront, as published), announced Jun 3, 2025. Source: SEC filing. source ↗
Jun 3, 2025 Partnership / licensing: $75M (upfront, as published); deal value up to $50M (kept separate from upfront), announced Jun 3, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 31

Record	Title	Phase	Status	Start	Primary completion
NCT03495882	A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)	Phase 1/Phase 2	Completed	Dec 18, 2017	Jul 15, 2022 (actual)
NCT05630183	A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer	Phase 2	Completed	Mar 27, 2023	Jan 5, 2026 (actual)
NCT06751524	Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval	Not listed	Available	Not listed	Not listed
NCT05572970	Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)	Not listed	Available	Not listed	Not listed
NCT03860272	Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer	Phase 1	Active, not recruiting	Mar 20, 2019	Jan 13, 2025 (actual)
NCT03894215	RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer	2	Terminated	Jun 1, 2019	Mar 26, 2025 (actual)
NCT05529316	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Phase 2	Active, not recruiting	Dec 12, 2022	2028-02 (estimated)
NCT05025085	A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors	Phase 1	Completed	Oct 4, 2021	Jul 11, 2023 (actual)
NCT05608044	A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer	Phase 2	Active, not recruiting	Nov 30, 2022	2027-09 (estimated)
NCT03104699	A Study of AGEN2034 in Advanced Tumors and Cervical Cancer	Phase 1/Phase 2	Completed	Apr 11, 2017	Jun 15, 2022 (actual)
NCT05377528	Study of AGEN1571 in Participants With Advanced Solid Tumors	Phase 1	Completed	Jul 19, 2022	Dec 23, 2024 (actual)
NCT02694822	AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy	Phase 1/Phase 2	Completed	2016-04	Mar 30, 2022 (actual)
NCT04121676	Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer	Phase 1	Completed	Sep 26, 2019	Feb 22, 2024 (actual)
NCT05033132	A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer	II	Withdrawn	Oct 1, 2021	Dec 30, 2024 (estimated)
NCT00081809	A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma	Phase 2	Completed	2000-03	2005-06 (actual)
NCT04943627	Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)	Phase 3	Withdrawn	Aug 2, 2021	Oct 22, 2021 (actual)
NCT04156100	A Study in Subjects With Advanced Solid Tumors	Phase 1	Terminated	Dec 10, 2019	Apr 8, 2021 (actual)
NCT04607200	AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma	Phase 2	Withdrawn	2021-02	Sep 13, 2021 (actual)
NCT03673020	Phase 1a Study to Evaluate Immunogenicity of ASV®	1	Completed	May 16, 2019	Feb 3, 2021 (actual)
NCT01687595	Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes	Phase 2	Completed	Oct 29, 2012	2013-09 (actual)
NCT01147536	Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence	Phase 2	Terminated	2010-01	2012-06 (actual)
NCT03411473	Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2	Terminated	Oct 4, 2017	May 1, 2018 (actual)
NCT02992977	Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer	Phase 1	Terminated	2017-01	2018-12 (actual)
NCT00033904	Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer	Phase 3	Completed	2000-06	2007-04 (actual)
NCT00039000	Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma	Phase 3	Completed	2002-03	2005-12 (actual)
NCT00082459	Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma	Phase 2	Terminated	2002-07	2005-12 (actual)
NCT00126178	Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer	Phase 3	Terminated	2005-05	2006-03 (actual)
NCT00058747	AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™	Phase 2	Terminated	2003-03	2006-04 (actual)
NCT00098085	Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer	Phase 2	Completed	2003-09	2007-11 (actual)
NCT00231049	Trial Evaluating Safety, Tolerability and Immune Response of AG-707	Phase 1	Completed	2006-03	Not listed
NCT00316511	Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma	Phase 1	Completed	2006-03	2008-06 (actual)

NIH awards 29

Annual award amounts. Total $6.3M.

Sep 22, 2016 NIH award 1R43CA203138-01A1 FY2016: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI GOSTISSA, MONICA; recipient as written: AGENUS, INC., LEXINGTON, MA. Validation and humanization of a PET imaging age source ↗
Sep 22, 2016 NIH award 1R43CA210714-01A1 FY2016: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI GOSTISSA, MONICA; recipient as written: AGENUS, INC., LEXINGTON, MA. Development of immuno-PET agents for the selecti source ↗
2003 NIH award 1R43AI055185-01 FY2003: $188,719 awarded for that fiscal year; activity R43 (SBIR); PI MO, ANNIE X. Y.; recipient as written: AGENUS, INC., LEXINGTON, MA. Heat Shock Protein based vaccine for Tuberculosis source ↗
Mar 5, 2001 NIH award 1R41AI049641-01 FY2001: $302,541 awarded for that fiscal year; activity R41 (STTR); PI CHANG, SANDRA PERREIRA; recipient as written: AGENUS, INC., LEXINGTON, MA. A P. falciparum MSP1 p42/QS-21 malaria vacci source ↗
Aug 21, 2000 NIH award 1R43AI048283-01 FY2000: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI MURPHY, CHERYL L; recipient as written: AGENUS, INC., LEXINGTON, MA. LIPID-BASED VACCINES FOR STAPHYLOCOCCUS AUREUS source ↗
Jul 21, 2000 NIH award 5R44AI040798-03 FY2000: $420,908 awarded for that fiscal year; activity R44 (SBIR); PI LECLAIR, KENNETH P; recipient as written: AGENUS, INC., LEXINGTON, MA. DEVELOPMENT OF LIPID VACCINES FOR TUBERCULOSIS source ↗
Jun 20, 2000 NIH award 1R43AI046821-01 FY2000: $127,989 awarded for that fiscal year; activity R43 (SBIR); PI BELTZ, GERALD A; recipient as written: AGENUS, INC., LEXINGTON, MA. CD1 PRESENTED VACCINES TO PREVENT CHLAMYDIA INFECTI source ↗
Jul 22, 1999 NIH award 2R44AI040798-02A1 FY1999: $452,858 awarded for that fiscal year; activity R44 (SBIR); PI LECLAIR, KENNETH P; recipient as written: AGENUS, INC., LEXINGTON, MA. DEVELOPMENT OF LIPID VACCINES FOR TUBERCULOSIS source ↗
Sep 30, 1995 NIH award 5R44AI030837-03 FY1995: $292,576 awarded for that fiscal year; activity R44 (SBIR); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE source ↗
Sep 28, 1995 NIH award 5R29AI035193-03 FY1995: $126,005 awarded for that fiscal year; activity R29 (OTHER_NIH); PI WU, JIA-YAN; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT-BASED VACCINES AGAINST MYCOBACTER source ↗
Sep 29, 1994 NIH award 2R44AI030837-02 FY1994: $256,247 awarded for that fiscal year; activity R44 (SBIR); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE source ↗
Sep 22, 1994 NIH award 5R01AI033560-03 FY1994: $199,218 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT ENHANCED PNEUMOCOCCA source ↗
Jul 20, 1994 NIH award 5U01AI028167-05 FY1994: $336,029 awarded for that fiscal year; activity U01 (OTHER_NIH); PI KENSIL, CHARLOTTE A; recipient as written: AGENUS, INC., LEXINGTON, MA. HIV 1/2 (AIDS) VACCINE DEVELOPMENT USING N source ↗
Jul 20, 1994 NIH award 5U01AI033223-03 FY1994: $197,232 awarded for that fiscal year; activity U01 (OTHER_NIH); PI KENSIL, CHARLOTTE A; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT BASED HIV 1 SUBUNIT VACCI source ↗
May 20, 1994 NIH award 5R29AI035193-02 FY1994: $111,363 awarded for that fiscal year; activity R29 (OTHER_NIH); PI WU, JIA-YAN; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT-BASED VACCINES AGAINST MYCOBACTER source ↗
Sep 29, 1993 NIH award 1R29AI035193-01 FY1993: $111,508 awarded for that fiscal year; activity R29 (OTHER_NIH); PI WU, JIA-YAN; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT-BASED VACCINES AGAINST MYCOBACTER source ↗
Aug 28, 1993 NIH award 5R01AI033560-02 FY1993: $172,397 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT ENHANCED PNEUMOCOCCA source ↗
Jul 16, 1993 NIH award 5U01AI028167-04 FY1993: $313,411 awarded for that fiscal year; activity U01 (OTHER_NIH); PI KENSIL, CHARLOTTE A; recipient as written: AGENUS, INC., LEXINGTON, MA. HIV-1/2 (AIDS) VACCINE DEVELOPMENT USING N source ↗
Jul 2, 1993 NIH award 5U01AI033223-02 FY1993: $197,234 awarded for that fiscal year; activity U01 (OTHER_NIH); PI KENSIL, CHARLOTTE A; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT BASED HIV-1 SUBUNIT VACCI source ↗
Sep 30, 1992 NIH award 1R01AI033560-01 FY1992: $149,461 awarded for that fiscal year; activity R01 (OTHER_NIH); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT ENHANCED PNEUMOCOCCA source ↗
Aug 21, 1992 NIH award 5U01AI028167-03 FY1992: $271,160 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NEWMAN, MARK J.; recipient as written: AGENUS, INC., LEXINGTON, MA. HIV-1/2 (AIDS) VACCINE DEVELOPMENT USING NOVEL source ↗
Jul 31, 1992 NIH award 1U01AI033223-01 FY1992: $187,632 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NEWMAN, MARK J.; recipient as written: AGENUS, INC., LEXINGTON, MA. SAPONIN ADJUVANT BASED HIV-1 SUBUNIT VACCINES source ↗
Sep 29, 1991 NIH award 1R43AI030837-01 FY1991: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI COUGHLIN, RICHARD THOMAS; recipient as written: AGENUS, INC., LEXINGTON, MA. RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE source ↗
Sep 24, 1991 NIH award 5U01AI028167-02 FY1991: $309,572 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NEWMAN, MARK J.; recipient as written: AGENUS, INC., LEXINGTON, MA. HIV-1/2 (AIDS) VACCINE DEVELOPMENT USING NOVEL source ↗
May 14, 1991 NIH award 1R43AI030290-01A1 FY1991: $49,071 awarded for that fiscal year; activity R43 (SBIR); PI KENSIL, CHARLOTTE A; recipient as written: AGENUS, INC., LEXINGTON, MA. RECOMBINANT SUBUNIT VACCINE FOR HUMAN CYTOMEGA source ↗
Sep 30, 1990 NIH award 1U01AI028167-01A1 FY1990: $340,718 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NEWMAN, MARK J.; recipient as written: AGENUS, INC., LEXINGTON, MA. SIVAGM PATHOGENESIS/VACCINE DEVELOPMENT IN M source ↗
Aug 30, 1990 NIH award 5R44AI026417-03 FY1990: $197,744 awarded for that fiscal year; activity R44 (SBIR); PI HUNG, CHUNG-HO; recipient as written: AGENUS, INC., LEXINGTON, MA. PURIFICATION OF HTLV-1 RECOMBINANT ENVELOPE ANTIGEN source ↗
Aug 29, 1989 NIH award 2R44AI026417-02 FY1989: $231,880 awarded for that fiscal year; activity R44 (SBIR); PI HUNG, CHUNG-HO; recipient as written: AGENUS, INC., LEXINGTON, MA. PURIFICATION OF HTLV-1 RECOMBINANT ENVELOPE ANTIGEN source ↗
Mar 23, 1988 NIH award 1R43AI026417-01 FY1988: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI HUNG, CHUNG-HO; recipient as written: AGENUS, INC., LEXINGTON, MA. PURIFICATION OF HTLV-I RECOMBINANT ENVELOPE ANTIGEN source ↗